Nuestra empresa

HeartSine Technologies, a division of Physio-Control, which is now part of Stryker, advances the deployment of lifesaving defibrillation therapy for the treatment of sudden cardiac arrest in non-traditional areas of care.

HeartSine was founded in 1998 to continue innovative development of advanced lifesaving products for the treatment of sudden cardiac arrest. Our passion to innovate began in 1967, when we invented the first mobile defibrillator and changed the way the world delivered emergency care. In the years since, HeartSine has continued its passion to innovate by advancing mobile defibrillation and lifesaving technology.

Our flagship product, the HeartSine samaritan PAD (Public Access Defibrillator), which is designed for ease of use, has been deployed in thousands of facilities. As HeartSine AED products are currently available in over 30 languages and are poised to save lives in more than 70 countries, the HeartSine samaritan PAD is recognized around the world for lifesaving technology.

Our Mission

We are committed to providing innovative, intelligent, lifesaving solutions for the assessment and prevention of sudden cardiac death. Our mission is to:

  • Expand the frontiers of medical research with patented technologies that address clinical requirements and meet the needs of the market with unsurpassed quality and reliability
  • Deal with customers and suppliers with the highest level of ethics and fairness
  • Employ high-quality and motivated employees and promote an optimal environment for them through respect, a good workplace and rewards
  • Offer products at a fair price, strive to reduce costs and earn a reasonable profit

Research and Development

HeartSine’s technology and innovation is based on a proven history of development in the field of cardiac defibrillation that began in the 1960s. Our R&D is spearheaded by an impressive team of technology experts and renowned luminaries in the industry.

A renowned panel of key authorities in the field of resuscitation employ their wealth of clinical experience on our Clinical Advisory Board to support our development of ground breaking innovative technology. The board’s prominent members include Dr. Ben Abella, Dr. Rudi Koster, Dr. David McEneaney, Dr. Doug Weaver and Chair Prof. Jennifer Adgey.

To augment and enhance our in-house development activities, we have established links in Northern Ireland with the University of Ulster, Northern Ireland Ambulance Service, Craigavon Area Hospital and the Royal Victoria Hospital, a world renowned teaching and research hospital on our doorstep. In addition, we have initiated research with University of Texas Southwestern Medical Center, the world leading institution for the advancement of resuscitation therapies.